Clinical trials: Respiratory Allergy
Asthma
Repeat Dose Safety Study for Compound to Treat Asthma
The purpose of this study is to describe the safety and tolerability of single and repeat oral doses of GSK1440115 in healthy volunteers.
- Trial name
- NCT01202214
- Testing
- 1440115
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Accenture
Asthma, Moderate Asthma
Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma
Purpose of this study is to assess the safety and tolerability of multiple ascending subcutaneous doses of REGN3500 to moderate asthmatics.
- Trial name
- NCT02999711
- Testing
- REGN3500
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma, Lung Diseases
Effect of PUR003 on Asthma
PUR003 is an inhaled substance that is proposed to assist in the treatment of asthma. Study objectives are to : 1. to evaluate the safety of PUR003 in subjects with asthma, and 2.
- Conditions
- Asthma, Lung Diseases, Bronchial Diseases
- Trial name
- NCT00989521
- Testing
- PUR003
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Pulmatrix Inc.
Asthma
Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)
This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) versus MF for 26 weeks.
- Trial name
- NCT00383552
- Testing
- Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID, Mometasone Furoate MDI (MF MDI), Formoterol Fumarate 10 mcg
- Volunteers
- 746 people
- Sponsor
- Organon and Co
Small Cell Lung Cancer
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
- Trial name
- NCT03898791
- Testing
- LY3295668 Erbumine
- Where
- 40 sites in United States, Belgium and 6 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Asthma
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA134a propelled Metered Dose Inhaler (MDI) (E004), using a stable isotope deuterium-labeled epinephrine…
- Trial name
- NCT01255709
- Testing
- Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA, Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice
This is a prospective, non-comparative, open, observational study.
- Trial name
- NCT01438255
- Where
- South Korea
- Volunteers
- 274 people
- Sponsor
- Handok Inc.
Asthma
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus
The purposes of this study is to compare the test products Salmeterol/fluticasone Easyhaler with marketed product Seretide Diskus in terms of the drug absorbed into the blood stream
- Trial name
- NCT02162485
- Testing
- Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal, Seretide Diskus
- Where
- Finland
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
- Trial name
- KALOS (NCT04609878)
- Testing
- BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg
- Where
- 360 sites in United States, Argentina and 19 more
- Volunteers
- 2,274 people
- Sponsor
- AstraZeneca
Allergic Rhinitis
Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays
The primary objective is to assess the effect of fluticasone propionate (FLU) on the relative bioavailability (AUC0-∞) of azelastine hydrochloride (AZE) when administered as fixed AZE-FLU combination product (TEST) compared to a…
- Trial name
- NCT01190852
- Testing
- Azelastine, Fluticasone, Azelastine mono, Azelastine
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MEDA Pharma GmbH & Co. KG
Asthma
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
The purpose of this study is to evaluate the long-term safety of the fixed combination asthma drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult and adolescent patients with mild to…
- Trial name
- NCT00394121
- Testing
- Fluticasone propionate/formoterol fumarate
- Where
- 28 sites in Germany, Hungary and 3 more
- Volunteers
- 400 people
- Sponsor
- SkyePharma AG
Asthma
The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)
This study will investigate the additive effect of montelukast (MK0476) taken along with inhaled beclomethasone versus inhaled beclomethasone alone.
- Trial name
- NCT00911547
- Testing
- montelukast sodium, beclomethasone
- Volunteers
- 642 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis
Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)
This is study of LMC, phenylephrine, and placebo in subjects with SAR. There are three visits: At Visit 1, subjects will be evaluated for participation and, if they qualify, will attend Visit 2 for priming.
- Trial name
- NCT00423995
- Testing
- Loratadine/montelukast combination
- Volunteers
- 379 people
- Sponsor
- Organon and Co
Severe Asthma
ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab
This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical…
- Trial name
- ANANKE (NCT04272463)
- Testing
- No intervention
- Where
- 18 sites in Italy
- Volunteers
- 217 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Seasonal, Asthma
Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 671800 ED using three dose levels of BI 671800 ED (50 mg, 200 mg and 400 mg), administered twice daily compared to FP (fluticasone…
- Trial name
- NCT01007721
- Testing
- BI 67100 ED 25 mg, BI 671800 ED 100 mg
- Where
- Germany
- Volunteers
- 146 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Rhinitis, Allergic, Perennial
Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS
The purpose of this replicate study to FFU105924 is to provide data on subject preference of FFNS as compared with FPNS.
- Trial name
- NCT00519636
- Testing
- FPNS, FFNS
- Where
- 28 sites in United States
- Volunteers
- 360 people
- Sponsor
- GlaxoSmithKline
House Dust Mite Allergy
A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet
The primary aim of this trial is to evaluate the efficacy of the ALK house dust mite tablet given once daily compared to a placebo tablet in the treatment of house dut mite allergic rhinits.
- Trial name
- MT-06 (NCT01454544)
- Testing
- AIT Tablet
- Where
- France
- Volunteers
- 992 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis
OC000459 Dose Finding Study in Hay Fever Sufferers.
The primary objective of this study is to evaluate a range of dose levels for efficacy in the control of symptoms of allergic rhinitis
- Trial name
- NCT00697281
- Testing
- OC000459
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Oxagen Ltd
Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
This study is in patients with seasonal allergic rhinitis(SAR)and will compare the effect versus placebo of repeat doses of intranasal GSK256066 using the Vienna Challenge Chamber.
- Trial name
- NCT00377728
- Testing
- GSK256066
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.